Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 45 | 2025 | 201 | 12.610 |
Why?
|
| Infant, Very Low Birth Weight | 37 | 2022 | 188 | 8.810 |
Why?
|
| Intensive Care Units, Neonatal | 39 | 2025 | 210 | 7.430 |
Why?
|
| Breast Feeding | 32 | 2025 | 170 | 6.720 |
Why?
|
| Mothers | 24 | 2025 | 186 | 5.830 |
Why?
|
| Infant, Premature | 40 | 2025 | 218 | 5.370 |
Why?
|
| Infant, Newborn | 63 | 2025 | 642 | 4.720 |
Why?
|
| Enterocolitis, Necrotizing | 14 | 2022 | 49 | 3.170 |
Why?
|
| Lactation | 11 | 2021 | 62 | 2.470 |
Why?
|
| Infant | 27 | 2025 | 564 | 2.360 |
Why?
|
| Infant Nutritional Physiological Phenomena | 15 | 2025 | 80 | 2.340 |
Why?
|
| Milk Banks | 7 | 2020 | 22 | 2.280 |
Why?
|
| Patient Discharge | 9 | 2025 | 158 | 2.170 |
Why?
|
| Gestational Age | 14 | 2025 | 89 | 1.960 |
Why?
|
| Infant, Premature, Diseases | 6 | 2020 | 30 | 1.880 |
Why?
|
| Enteral Nutrition | 6 | 2022 | 66 | 1.770 |
Why?
|
| Child Development | 6 | 2020 | 73 | 1.500 |
Why?
|
| Female | 54 | 2025 | 15212 | 1.470 |
Why?
|
| Infant Formula | 4 | 2020 | 22 | 1.400 |
Why?
|
| Humans | 69 | 2025 | 27072 | 1.330 |
Why?
|
| Intensive Care, Neonatal | 7 | 2020 | 37 | 1.310 |
Why?
|
| Breast Milk Expression | 10 | 2020 | 42 | 1.240 |
Why?
|
| Social Support | 3 | 2019 | 196 | 1.170 |
Why?
|
| Residence Characteristics | 2 | 2019 | 214 | 1.040 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 302 | 0.890 |
Why?
|
| Gastroschisis | 2 | 2020 | 5 | 0.840 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2020 | 15 | 0.830 |
Why?
|
| Prospective Studies | 14 | 2021 | 1778 | 0.810 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 88 | 0.810 |
Why?
|
| Health Care Costs | 4 | 2020 | 75 | 0.800 |
Why?
|
| Retrospective Studies | 15 | 2025 | 3538 | 0.790 |
Why?
|
| Goals | 3 | 2017 | 43 | 0.780 |
Why?
|
| Male | 34 | 2025 | 14772 | 0.770 |
Why?
|
| Pregnancy | 5 | 2025 | 336 | 0.740 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2016 | 18 | 0.730 |
Why?
|
| Vitamin D | 1 | 2021 | 39 | 0.720 |
Why?
|
| Infant, Low Birth Weight | 2 | 2019 | 18 | 0.710 |
Why?
|
| Neonatology | 1 | 2020 | 4 | 0.700 |
Why?
|
| Birth Weight | 7 | 2022 | 46 | 0.690 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 32 | 0.680 |
Why?
|
| United States | 7 | 2025 | 2035 | 0.670 |
Why?
|
| Infant Care | 3 | 2016 | 19 | 0.660 |
Why?
|
| Child of Impaired Parents | 1 | 2019 | 10 | 0.650 |
Why?
|
| Diet | 3 | 2022 | 220 | 0.640 |
Why?
|
| Hospitalization | 5 | 2020 | 300 | 0.630 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 45 | 0.630 |
Why?
|
| Oxidative Stress | 2 | 2018 | 94 | 0.610 |
Why?
|
| Aftercare | 1 | 2018 | 24 | 0.600 |
Why?
|
| Anxiety | 1 | 2019 | 156 | 0.600 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2017 | 164 | 0.590 |
Why?
|
| Adult | 15 | 2025 | 7831 | 0.580 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 77 | 0.570 |
Why?
|
| Nervous System | 1 | 2017 | 11 | 0.560 |
Why?
|
| Maternal Behavior | 1 | 2017 | 11 | 0.560 |
Why?
|
| Pregnancy in Adolescence | 1 | 2017 | 11 | 0.550 |
Why?
|
| Stress, Psychological | 1 | 2019 | 235 | 0.550 |
Why?
|
| Educational Status | 5 | 2019 | 293 | 0.530 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 231 | 0.520 |
Why?
|
| Quality of Health Care | 1 | 2017 | 102 | 0.510 |
Why?
|
| Quality Improvement | 1 | 2017 | 138 | 0.500 |
Why?
|
| Sepsis | 2 | 2017 | 113 | 0.500 |
Why?
|
| Informed Consent | 1 | 2015 | 23 | 0.500 |
Why?
|
| Depression | 1 | 2019 | 444 | 0.490 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 47 | 0.490 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 28 | 0.490 |
Why?
|
| Bacteria | 1 | 2016 | 70 | 0.490 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 158 | 0.430 |
Why?
|
| Decision Making | 1 | 2015 | 223 | 0.430 |
Why?
|
| Oxygen | 2 | 2003 | 68 | 0.390 |
Why?
|
| Postpartum Period | 3 | 2021 | 24 | 0.380 |
Why?
|
| Tissue Donors | 3 | 2021 | 79 | 0.360 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 891 | 0.340 |
Why?
|
| Sleep | 2 | 2003 | 328 | 0.320 |
Why?
|
| Nutritive Value | 2 | 2020 | 25 | 0.320 |
Why?
|
| Nutritional Status | 2 | 2020 | 58 | 0.310 |
Why?
|
| Infant, Extremely Low Birth Weight | 3 | 2017 | 23 | 0.310 |
Why?
|
| Models, Biological | 2 | 2009 | 322 | 0.290 |
Why?
|
| Cohort Studies | 8 | 2022 | 1890 | 0.270 |
Why?
|
| Child Language | 2 | 2017 | 19 | 0.270 |
Why?
|
| Age Factors | 2 | 2020 | 766 | 0.260 |
Why?
|
| Incidence | 7 | 2020 | 759 | 0.260 |
Why?
|
| Qualitative Research | 2 | 2017 | 114 | 0.260 |
Why?
|
| Infant, Extremely Premature | 2 | 2022 | 11 | 0.250 |
Why?
|
| Bottle Feeding | 2 | 2016 | 16 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 370 | 0.250 |
Why?
|
| Anthropometry | 1 | 2005 | 34 | 0.250 |
Why?
|
| Bedding and Linens | 2 | 2003 | 6 | 0.240 |
Why?
|
| Carbon Dioxide | 2 | 2003 | 19 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 278 | 0.240 |
Why?
|
| Child | 5 | 2022 | 1295 | 0.220 |
Why?
|
| Motor Activity | 2 | 2017 | 323 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1368 | 0.220 |
Why?
|
| Risk Factors | 4 | 2017 | 2302 | 0.220 |
Why?
|
| Prone Position | 1 | 2003 | 33 | 0.210 |
Why?
|
| Risk | 2 | 2020 | 204 | 0.200 |
Why?
|
| Maternal Age | 2 | 2019 | 15 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 123 | 0.190 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 72 | 0.190 |
Why?
|
| Respiration | 1 | 2001 | 35 | 0.190 |
Why?
|
| Young Adult | 5 | 2019 | 1994 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 1 | 2021 | 11 | 0.180 |
Why?
|
| Arachidonic Acid | 1 | 2021 | 17 | 0.180 |
Why?
|
| Directive Counseling | 2 | 2019 | 12 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2021 | 66 | 0.180 |
Why?
|
| Time Factors | 3 | 2018 | 1433 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 15 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2020 | 17 | 0.180 |
Why?
|
| Premature Birth | 1 | 2020 | 11 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 292 | 0.170 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 37 | 0.170 |
Why?
|
| Intestinal Atresia | 1 | 2020 | 1 | 0.170 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 132 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 261 | 0.170 |
Why?
|
| Intestine, Small | 1 | 2020 | 30 | 0.170 |
Why?
|
| Linear Models | 2 | 2017 | 247 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 75 | 0.160 |
Why?
|
| Intestinal Mucosa | 2 | 2018 | 156 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 161 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 112 | 0.160 |
Why?
|
| Contraception Behavior | 1 | 2019 | 5 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 329 | 0.160 |
Why?
|
| Logistic Models | 2 | 2017 | 395 | 0.160 |
Why?
|
| Inflammation | 2 | 2018 | 272 | 0.160 |
Why?
|
| Nutritional Support | 1 | 2018 | 24 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 67 | 0.150 |
Why?
|
| Food, Fortified | 1 | 2018 | 9 | 0.150 |
Why?
|
| Cognition | 2 | 2017 | 1339 | 0.150 |
Why?
|
| F2-Isoprostanes | 1 | 2018 | 7 | 0.150 |
Why?
|
| Cell Death | 1 | 2018 | 45 | 0.150 |
Why?
|
| Chicago | 3 | 2016 | 949 | 0.150 |
Why?
|
| Energy Intake | 1 | 2018 | 83 | 0.140 |
Why?
|
| Length of Stay | 1 | 2020 | 313 | 0.140 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2017 | 2 | 0.140 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 7 | 0.140 |
Why?
|
| Protective Factors | 1 | 2017 | 26 | 0.140 |
Why?
|
| Anemia | 1 | 2017 | 34 | 0.140 |
Why?
|
| Probiotics | 1 | 2017 | 17 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2017 | 67 | 0.140 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 56 | 0.140 |
Why?
|
| Oligosaccharides | 1 | 2017 | 18 | 0.140 |
Why?
|
| Peer Group | 1 | 2017 | 35 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1792 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 38 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 120 | 0.130 |
Why?
|
| Bacteremia | 1 | 2017 | 101 | 0.130 |
Why?
|
| Return to Work | 1 | 2016 | 65 | 0.130 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 43 | 0.130 |
Why?
|
| Phylogeny | 1 | 2016 | 51 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 44 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 58 | 0.130 |
Why?
|
| Illinois | 1 | 2016 | 250 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2013 | 50 | 0.120 |
Why?
|
| Feces | 1 | 2016 | 103 | 0.120 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2015 | 4 | 0.120 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 14 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2015 | 132 | 0.120 |
Why?
|
| Adolescent | 3 | 2017 | 2172 | 0.120 |
Why?
|
| Cost Savings | 1 | 2015 | 32 | 0.120 |
Why?
|
| Retinopathy of Prematurity | 1 | 2014 | 7 | 0.110 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 2 | 0.110 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 3 | 0.110 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 5 | 0.110 |
Why?
|
| Postnatal Care | 1 | 2013 | 7 | 0.110 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 9 | 0.110 |
Why?
|
| Feeding Methods | 1 | 2013 | 5 | 0.100 |
Why?
|
| Propensity Score | 1 | 2013 | 36 | 0.100 |
Why?
|
| Pharmacopoeias as Topic | 1 | 2012 | 5 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 32 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2013 | 59 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2012 | 24 | 0.100 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2003 | 7 | 0.100 |
Why?
|
| Direct Service Costs | 1 | 2012 | 4 | 0.100 |
Why?
|
| Tidal Volume | 2 | 2003 | 13 | 0.100 |
Why?
|
| Pediatrics | 1 | 2012 | 39 | 0.100 |
Why?
|
| Sudden Infant Death | 2 | 2003 | 37 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2012 | 62 | 0.100 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Codon, Terminator | 1 | 2011 | 3 | 0.100 |
Why?
|
| Biomarkers | 3 | 2020 | 562 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 2 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2020 | 587 | 0.090 |
Why?
|
| Fluconazole | 1 | 2010 | 8 | 0.090 |
Why?
|
| Cultured Milk Products | 1 | 2009 | 3 | 0.080 |
Why?
|
| Mycoses | 1 | 2010 | 21 | 0.080 |
Why?
|
| Milk | 1 | 2009 | 14 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 30 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2010 | 43 | 0.080 |
Why?
|
| Animals | 5 | 2020 | 3642 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 420 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 474 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 381 | 0.070 |
Why?
|
| Ventricular Pressure | 1 | 1996 | 2 | 0.060 |
Why?
|
| Lidocaine | 1 | 1996 | 23 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 35 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 85 | 0.060 |
Why?
|
| Ion Channel Gating | 1 | 1996 | 187 | 0.060 |
Why?
|
| Blood Gas Analysis | 1 | 2003 | 6 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2003 | 9 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2003 | 19 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 32 | 0.050 |
Why?
|
| Polysomnography | 1 | 2003 | 84 | 0.050 |
Why?
|
| Face | 1 | 2003 | 29 | 0.050 |
Why?
|
| Air | 1 | 2001 | 4 | 0.050 |
Why?
|
| Methods | 1 | 2001 | 12 | 0.050 |
Why?
|
| Environment | 1 | 2001 | 42 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 15 | 0.040 |
Why?
|
| Ranibizumab | 1 | 2020 | 2 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2020 | 3 | 0.040 |
Why?
|
| Choroid Diseases | 1 | 2020 | 3 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 2020 | 5 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2020 | 21 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2020 | 11 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 31 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2001 | 32 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2001 | 50 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 75 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 406 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 120 | 0.040 |
Why?
|
| Intention | 1 | 2019 | 21 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 458 | 0.040 |
Why?
|
| Oceania | 1 | 2018 | 3 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 10 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 10 | 0.040 |
Why?
|
| North America | 1 | 2018 | 41 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 58 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 21 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 311 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 12 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 347 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2018 | 43 | 0.040 |
Why?
|
| Weight Gain | 1 | 2018 | 64 | 0.040 |
Why?
|
| Income | 1 | 2018 | 80 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 94 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2017 | 60 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 189 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 139 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3485 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 270 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 641 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 312 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 56 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 9 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2015 | 10 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 17 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 181 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2015 | 113 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 273 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 79 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 624 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2001 | 916 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 54 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 2013 | 2 | 0.030 |
Why?
|
| Ampicillin | 1 | 2013 | 5 | 0.030 |
Why?
|
| Gentamicins | 1 | 2013 | 17 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2013 | 18 | 0.030 |
Why?
|
| Cardiology | 1 | 2012 | 44 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2011 | 2 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 102 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 131 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 145 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2011 | 96 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 100 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 17 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 1395 | 0.020 |
Why?
|
| Cholestasis | 1 | 2010 | 8 | 0.020 |
Why?
|
| Colostrum | 1 | 2010 | 5 | 0.020 |
Why?
|
| Candidiasis | 1 | 2010 | 24 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 443 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 879 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 785 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1996 | 15 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 1996 | 8 | 0.020 |
Why?
|
| Sodium Channels | 1 | 1996 | 13 | 0.020 |
Why?
|
| Verapamil | 1 | 1996 | 25 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 31 | 0.020 |
Why?
|
| Lymphoma | 1 | 2001 | 35 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 161 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 198 | 0.010 |
Why?
|